Group 1 - The Swiss franc is experiencing a narrow trading range against the US dollar, currently around 0.8014, with a downward trend since the beginning of the year, having recently dropped to a short-term low of 0.7970, a daily decline of 0.55% [1] - The Swiss National Bank (SNB) has maintained a 0% policy interest rate and reiterated its commitment to actively participate in the foreign exchange market, indicating that the current expansionary monetary policy conditions are appropriate [1][2] - The stability of the Swiss franc against the euro is attributed to the SNB's foreign exchange interventions and zero interest rate policy, with the euro to Swiss franc exchange rate currently at 0.9287, down from 0.9395 at the beginning of the year [1] Group 2 - The current monetary policy's stimulus effects are fully transmitted, with credit growth and money supply data reflecting the policy's impact, which supports mid-term price stability [2] - The SNB's reluctance to reintroduce negative interest rates is due to significant side effects on pension systems, reinforcing expectations of policy stability [2] - The "loose US, stable Swiss" policy framework has narrowed the interest rate differential between the US and Switzerland, driving the decline of the USD/CHF exchange rate [2] Group 3 - Technical analysis indicates that the USD/CHF exchange rate is in a short-term consolidation phase, with key support at the previous low of 0.7970 and resistance around 0.8020-0.8030 [3] - Recent trading volumes for the USD/CHF pair remain low, indicating a lack of clear market direction and a need for a breakout at key levels to confirm future trends [3] - The EUR/CHF exchange rate is expected to maintain a range between 1.08 and 1.09, showing no clear breakout signals in the short term [3]

Core Viewpoint - The Swiss Franc (CHF) is experiencing a stable performance against the Euro and slight fluctuations against the US Dollar, supported by the Swiss National Bank's (SNB) zero interest rate policy and its role as a safe-haven currency, despite pressures from export challenges and US policy constraints [1][2]. Group 1: Currency Performance - As of January 14, 2026, the CHF is trading in the range of 0.8750-0.8800 against the USD, influenced by the SNB's zero interest rate policy and safe-haven demand, while facing pressure from exports and US policy [1]. - The CHF is stable against the Euro, anchored in the 1.08-1.09 range, due to the SNB's foreign exchange interventions and zero interest rate policy [1]. - The CHF has appreciated nearly 2% year-to-date against the USD, although its appreciation potential is limited by US trade policies [1]. Group 2: Economic Outlook - The Swiss Economic Association forecasts a slowdown in GDP growth from 1.2% in 2025 to 1.0% in 2026, with declines in sales for technology and watchmaking sectors, and an increase in unemployment from 2.8% to 3.0% [2]. - The SNB's ability to operate is constrained by US policies, as Switzerland has been labeled a currency manipulator and is now subject to tariff considerations, creating political risks for the SNB's market interventions [2]. Group 3: Monetary Policy and Market Sentiment - The zero interest rate policy is a key stabilizing factor for the CHF, with the SNB maintaining this rate since June 2025 to prevent excessive appreciation and support core export industries [1]. - Market participants are closely monitoring SNB policies, US trade developments, and safe-haven sentiment in the short term, while focusing on export and real estate data in the long term [2]. - The average inflation rate for 2026 is projected at 0.4%, which is unlikely to drive policy adjustments [2].

Major Events - GCL-Poly Energy (00451) plans to issue 186.5 million subscription shares to partner with Pharos to accelerate the integration of Web3 and the renewable energy industry [1] - Hansoh Pharmaceutical (03692) receives drug registration certificate from the National Medical Products Administration for the fifth indication of Amelot (Ametinib Mesylate Tablets) [1] - Green Leaf Pharmaceutical (02186) has its application for the new indication of the innovative drug Ruoxinlin for the treatment of generalized anxiety disorder accepted in China [1] - Xianjian Technology (01302) receives formal registration approval from the National Medical Products Administration for the G-iliacTM Pro iliac artery covered stent system [1] - Meirui Health International (02327) plans to acquire 100% equity of Jiangsu Yide for 125 million yuan [1] - Century International (00959) joint venture signs a memorandum of understanding with WPT to jointly develop, operate, and commercialize mobile applications [1] Operating Performance - Fast Retailing (06288) reports first-quarter earnings with a net profit attributable to shareholders of 147.445 billion yen, an increase of 11.7% year-on-year [1] - Agile Group (01813) reports December pre-sale amount of 420 million yuan, a decrease of 56.7% year-on-year [1] - Baolong Real Estate (01238) projects total contract sales of approximately 7.272 billion yuan for 2025, a decrease of 43.13% year-on-year [1] - China General Nuclear Power (01816) expects total on-grid electricity of approximately 2,326.48 billion kilowatt-hours for 2025, an increase of 2.36% year-on-year [1] - Lingbao Gold (03330) issues a profit warning, expecting net profit for the 2025 fiscal year to be approximately 1.503 to 1.573 billion yuan, an increase of about 115% to 125% year-on-year [1]

Group 1 - Germany's trade dynamics have shifted, with the U.S. surpassing China as its largest trading partner in 2024, marking a significant change in trade relationships [1][3] - The total value of goods exported from Germany to the U.S. reached €252.8 billion, while exports to China fell to approximately €235 billion, resulting in a shift of €65 billion in trade surplus towards the U.S. [1] - The DAX index surged nearly 600 points within four weeks, reflecting positive market sentiment towards this strategic pivot [1] Group 2 - Major German companies are experiencing a stark contrast in performance, with BMW reporting a 13% drop in sales in China, while North American sales increased by 11% [4] - Volkswagen's profit margins in its Chinese joint ventures have fallen below 3%, while margins in the U.S. remain above 5%, prompting a shift in investment towards U.S. electric vehicle production [4] - The pharmaceutical company Boehringer Ingelheim has relocated its next-generation core active ingredient production to Boston, citing faster clinical approvals and favorable tax incentives as key reasons [6] Group 3 - German companies are increasingly seeking refuge in the U.S. due to competitive pressures from local Chinese brands, which have significantly reduced the cost of electric vehicles [6] - The tightening of regulations has led to a decline in Chinese investments in German startups, with over 30 acquisition applications stalled in the past year [8] - The shift in investment focus is evident as Chinese capital is now more inclined to flow towards Budapest and Belgrade rather than Frankfurt and Düsseldorf [8]

央视网消息：据"网信中国"微信公众号消息，今年以来，中央网信办举报中心持续畅通网络举报渠道，强化涉仿冒假冒网站举报受理处置工作，根据网 民提供的线索，协调有关部门逐一查证、及时处置违法违规仿冒假冒网站平台1418个，较去年同比增加1.7倍。 主要类型及情形 仿冒假冒网站通常以"领取补贴""充值消费""期刊征稿""商业合作""投资理财""考试招生"等名义，违规收集网民个人信息，诱导注册账号并缴费，实施诈 骗行为，相关网站服务器多设在境外，域名频繁跳转，侵害人民群众的合法权益和财产安全，社会危害大。 1.仿冒人社部、国家税务总局等国家机关网站317个。冒用国家机关名义，发布虚假"综合工薪补贴"、"退税通知"等，诱导网民输入身份证号码、银行卡 号码等个人隐私信息，导致信息泄露。 2.仿冒国家电网、中国石化等国有企事业单位网站323个。发布虚假投资、充值信息，诱导网民购买虚拟商品、虚假充值加油卡等，导致网民受骗。 3.仿冒《中国校外教育》《中华护理教育》等学术期刊网站250个。假借期刊名义骗取论文审稿费、版面费等费用，造成网民财产损失和个人文章泄露。 4.仿冒齐鲁制药、蜜雪冰城等民营企业网站135个。诱导网民开展虚假 ...

Core Viewpoint - The successful implementation of the "intellectual property + cash flow" technology loan in Meishan represents a significant step in financial innovation aimed at supporting the development of technology-driven small and medium-sized enterprises (SMEs) [1][6]. Group 1: Loan Implementation and Benefits - A pharmaceutical company in Hongya County received a loan of 5 million yuan within two weeks, marking the first "intellectual property + cash flow" technology loan in Meishan [1]. - The loan is part of a broader initiative to address the financing challenges faced by technology SMEs, particularly those with core technologies but limited assets [1][6]. - The loan process is streamlined, allowing companies to authorize data access online, enabling banks to automatically assess business conditions without requiring extensive documentation from the companies [4]. Group 2: Financial Innovation and Policy Support - The financing model combines cash flow credit assessment with intellectual property pledges, utilizing the national credit information sharing platform for SMEs [2][6]. - The Meishan government has introduced several policies to enhance the financial ecosystem, including the "Meishan Intellectual Property Pledge Financing Management Measures" and the "Guiding Opinions on Meishan's Science and Technology Finance Work" [6]. - Meishan ranks first in the province for credit structure indicators and third for credit support quality, indicating strong support for technological innovation and transformation loans [6]. Group 3: Cost Efficiency and Support Mechanisms - The loan allows for a fiscal subsidy of up to 40%, reducing the effective financing cost to as low as 1.5%, which can save the company approximately 50,000 yuan in interest over one year [4]. - The local bank has established a dedicated team to facilitate the loan process, ensuring that the entire procedure from application to fund disbursement is completed efficiently [4].

Core Viewpoint - The article suggests that global risk assets are expected to lead in 2026, with increasing market differentiation and a focus on diversified investment strategies around three key themes while being cautious of four major risks [1][6]. Macroeconomic Overview - The core scenario anticipates a 60% probability of a soft landing for the US economy, with the Federal Reserve expected to cut rates by 75 basis points to 3.0% by the end of 2026. Factors supporting growth include easing trade tensions, increased infrastructure and defense spending in Germany, and targeted stimulus policies in China. There is a 15% risk of a hard landing and a 25% risk of an "unlanding" scenario, with inflation stabilizing but remaining above pre-pandemic levels [1][6][65]. Investment Themes - **Theme 1: Stock Market Growth Driven by AI** The stock market is expected to rise alongside discussions around artificial intelligence, with AI-driven profit growth offsetting some valuation pressures. The recommendation is to overweight US and Asian (excluding Japan) stocks, with a focus on technology, healthcare, and utilities sectors [2][21][23]. - **Theme 2: Emerging Market Debt Outperforming Developed Markets** Emerging market debt, both in USD and local currencies, is seen as attractive due to improved fiscal fundamentals, yield advantages, and expectations of a weaker dollar, which can help mitigate interest rate risks in developed markets [2][28][23]. - **Theme 3: Diversification Tools Highlighted** Gold is expected to continue its upward trend, with target prices of $4,350 per ounce in 3 months and $4,800 per ounce in 12 months. Alternative investment strategies and currencies like the Japanese yen and offshore RMB are also considered important diversification tools [2][30][31]. Asset Class Allocation - In the bond sector, preference is given to emerging market debt and developed market investment-grade government bonds, with opportunities seen in US Treasury Inflation-Protected Securities and short-term high-yield bonds. In the stock sector, there is an underweight position in European (excluding the UK), Japanese, and UK stocks, while overweighting US tech stocks, high-yield stocks of non-financial state-owned enterprises in China, and the Hang Seng Tech Index [2][22][23]. Risk Factors - Key risks include underperformance of AI, potential chain reactions from credit events, shifts in Federal Reserve policy, and unexpected hawkish stances from the Bank of Japan, which could lead to market volatility [3][23][33].

Core Insights - European companies are increasingly investing in China, viewing it as a vital market with unique appeal, as highlighted by the statement from the general manager of Swiss company Medtronic [1] Group 1: Investment Trends - European investments in China have evolved from simple capacity layouts to deep-rooted, large-scale projects across the entire industrial chain [2] - Germany leads European investments in China, with Volkswagen investing €2.5 billion to expand its production and innovation center in Hefei, and BMW adding an additional ¥20 billion to its Shenyang base after a previous investment in a battery factory [3] - French pharmaceutical giant Sanofi has made a record investment of €1 billion to build an insulin production base in Beijing, marking a full industrial chain layout from raw materials to finished products [5] Group 2: Regional Contributions - Swiss and British companies are also actively investing in China, with Medtronic establishing its first production base in the Asia-Pacific region in Changzhou and subsequently adding €100 million to increase production capacity [7] - The number of British companies operating in China has reached 11,100, reflecting a double-digit growth in investments [7] Group 3: Competitive Advantages - The stable growth potential of the Chinese market is a key attraction, with China's GDP growth rate reaching 5% year-on-year in the first half of 2024, positioning it favorably among major economies [9] - China's complete industrial ecosystem supports multinational companies in achieving cost efficiency and effective supply chain integration [9] - Continuous improvements in the business environment in China, including the removal of foreign investment restrictions and enhanced support services, bolster investor confidence [10] Group 4: Innovation and Collaboration - China's focus on high-quality development and carbon neutrality offers new growth opportunities for European companies, with many viewing China as a critical testing ground for transitioning from traditional to new energy vehicles [10] - The collaboration between European companies and China is seen as mutually beneficial, providing advanced technology and management experience to China while allowing European firms to tap into a vibrant market [11]

证券研究报告 | 策略专题报告 2025 年 12 月 21 日 中央经济工作会议后，中财办、各部委有哪些增量表态？ ——国内外产业政策周报（1221） 本周国内政策方面，第一，中央经济工作会议后，中财办、各部委均有增量表 态，根据我们的梳理，建议重点关注五方面增量信息。第二，《保险公司资产 负债管理办法（征求意见稿）》发布，重点关注两方面变化。第三，各地十五 五建议稿出台。海外政策方面，本周美国九家药企达成协议，日央行加息落地、 美股科技大幅反弹。 专题报告 相关报告 1、《今年以来服务消费政策部 署梳理，美政府结束停摆——国 内外产业政策周报（1116）》 2、《黄金税收政策调整，美国 与亚洲多国达成合作——国内 外产业政策周报（1103）》 3、《发布会召开介绍和解读四 中全会精神，有哪些增量信息？ — — 国 内 外 产 业 政 策 周 报 （1025）》 4、《整治内卷聚焦价格治理， 特朗普威胁对华大幅加征关税 — — 国 内 外 产 业 政 策 周 报 （1011）》 5、《钢铁建材等稳增长方案陆 续印发，美国众议院代表团访华 — — 国 内 外 产 业 政 策 周 报 （0927）》 6、《三行 ...

Group 1 - The company, Qianjin Pharmaceutical (stock code: 600479), announced that it will hold its first extraordinary general meeting of shareholders for 2026 on January 12, 2026 [1]